Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Christos Chouaid

Centre Hospitalier Intercommunal de Créteil

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Daniel C. Christoph

Chief of Division

Xavier Quantin

David Pasquier

Université de Lille

Pilar Garrido López

Head Medical Oncology Department

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

Hervé Bischoff

Institut de Cancérologie Strasbourg

Jean Bernard Auliac

associeted professor

Centre Hospitalier Intercommunal de Créteil

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christos Chouaid

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Daniel C. Christoph

Xavier Quantin

David Pasquier

Pilar Garrido López

Hervé Bischoff

Jean Bernard Auliac

Make your next move.

Christos Chouaid

Research Interests

Explore related searches

Articles (20)

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration

Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale

Real-World Treatment Patterns and Survival in Patients with <i>ROS1</i>-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

Response to the Letter of Mehmet Mutlu Çatlı, Arif Hakan Önder

Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC—Considerations for Broader Applicability

Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study

Clinical characteristics and management of long survivors in extensive stage small cell lung cancer

The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany

Prognostic factors and outcomes of patients with advanced non-small-cell lung cancer treated with osimertinib: a retrospective database study

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review

Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)

Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study

Vieillissement et cancers

Impact of the COVID-19 pandemic on lung cancer diagnoses and mortality: A nationwide study in France

Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC)

Collaborators (6)

Daniel C. Christoph

Xavier Quantin

David Pasquier

Pilar Garrido López

Hervé Bischoff

Jean Bernard Auliac

Make your next move.